KRAS G12C mutation: from black sheep to key player in pancreatic cancer treatment

Related Experiment Video

Updated: Aug 6, 2025

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.7K

Rebecca Ibrahim1, Rita Khoury1, Tony Ibrahim1

  • 1Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, France.

Future Oncology (London, England)
|March 22, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

876
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

2.9K

Related Experiment Videos

Last Updated: Aug 6, 2025

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.7K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

876
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

2.9K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.3K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

9.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K

Articles linked to this work by shared authors, journal, and citation graph.

Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial.

The oncologist·2026

Correction: Khoury et al. Precision Medicine in Hematologic Malignancies: Evolving Concepts and Clinical Applications. Biomedicines 2025, 13, 1654.

Biomedicines·2026

HMGA2::NCOR2 fusion-driven giant cell tumors: Diagnosis and treatment.

Critical reviews in oncology/hematology·2026

Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.

Cancer·2026

Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives.

Current treatment options in oncology·2026

Understanding and managing agitation in neurocognitive disorders: Recent insights and global perspectives.

International psychogeriatrics·2026

Durvalumab plus etoposide-carboplatin for advanced digestive neuroendocrine carcinoma: a phase III trial (JCOG2107E).

Future oncology (London, England)·2026

Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092).

Future oncology (London, England)·2026

Real-world effectiveness of first-line chemoimmunotherapy versus chemotherapy in older adults with extensive-stage small cell lung cancer: an inverse probability treatment weighted analysis.

Future oncology (London, England)·2026

First-line osimertinib with or without chemotherapy for EGFR-mutant advanced NSCLC in China: a cost-effectiveness analysis.

Future oncology (London, England)·2026

TroFuse-032 study design: pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, triple-negative breast cancer or HR-low+/HER2- breast cancer.

Future oncology (London, England)·2026

Interleukin-6 as a prognostic biomarker in hepatocellular carcinoma treated with systemic therapy: a systematic review and meta-analysis.

Future oncology (London, England)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us